DrugPatentWatch Database Preview
Wellstat Therap Company Profile
What is the competitive landscape for WELLSTAT THERAP, and when can generic versions of WELLSTAT THERAP drugs launch?
There are two US patents protecting WELLSTAT THERAP drugs.
There are one hundred and seventy-two patent family members on WELLSTAT THERAP drugs in twenty-one countries and two supplementary protection certificates in two countries.
Summary for Wellstat Therap
| International Patents: | 172 |
| US Patents: | 2 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Wellstat Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wellstat Therap | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159-001 | Dec 11, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Wellstat Therap | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159-001 | Dec 11, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Wellstat Therap | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | 6,258,795 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Wellstat Therap | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Wellstat Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Wellstat Therap | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159-001 | Dec 11, 2015 | 5,968,914 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Non-Orange Book US Patents for Wellstat Therap
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,166,581 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | ➤ Sign Up |
| 7,105,498 | Acylated uridine and cytidine and uses thereof | ➤ Sign Up |
| 6,020,322 | Acyl deoxyribonucleoside derivatives and uses thereof | ➤ Sign Up |
| 5,968,914 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Wellstat Therap Drugs
Supplementary Protection Certificates for Wellstat Therap Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2017 00036 | Denmark | ➤ Sign Up | PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427 |
| 0889 | Netherlands | ➤ Sign Up | PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
